Response of HT29 Colorectal Xenograft Model to Cediranib Assessed with (18)F-FMISO PET, Dynamic Contrast-Enhanced and Diffusion-Weighted MRI

Cediranib (AZD2171, AstraZeneca, UK) is a small-molecule pan-VEGFR inhibitor. The tumor response to short-term cediranib treatment was studied using dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) MRI at 7 T as well as (18)F-fluoromisonidazle ((18)F-FMISO) PET and histological markers. R...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bokacheva, Louisa, Kotedia, Khushali, Reese, Megan, Ricketts, Sally-Ann, Halliday, Jane, Le, Carl H., Koutcher, Jason A., Carlin, Sean
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3524412/
https://ncbi.nlm.nih.gov/pubmed/22777834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/nbm.2830
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados